Email this article Chronic myeloid leukemia in children
- Authors: Borisevich M.V.1
-
Affiliations:
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
- Issue: Vol 15, No 4 (2016)
- Pages: 51-56
- Section: ЛЕЙКОЗЫ
- Submitted: 19.09.2018
- Published: 19.12.2016
- URL: https://hemoncim.com/jour/article/view/133
- DOI: https://doi.org/10.24287/1726-1708-2016-15-4-51-56
- ID: 133
Cite item
Full Text
Abstract
Chronic myeloid leukemia (CML) is rare in children up to the age of 18 years; for this reason, there are no accurate criteria of monitoring and individualization of treatment in this population group. This review of literature presents some features of the manifestation, the development of CML, the tyrosine kinase inhibitors treatment response and results of allogeneic stem cell transplantation in children. In addition this paper presents published data on the incidence of side effects during long-term imatinib therapy.
About the authors
Marina V. Borisevich
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Author for correspondence.
Email: borisevich10@mail.ru
Russian Federation
References
Supplementary files
